25 May 2013
Keywords: update, antisoma, as1404, substantial, survival, benefit, over
Article | 23 October 2006
UK cancer drug developer Antisoma has reported strong final data from a Phase II trial of AS1404 in non-small cell ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 October 2006
24 May 2013
© 2013 thepharmaletter.com